An assessment of change in asthma control among adolescents and adults with persistent asthma in mometasone furoate/formoterol fumarate clinical trials

Journal of Asthma

Volumn 48, Issue 1, 2011, Pages 48-56

  Wyrwich, Kathleen W ^a   Ireland, Andrea M ^a   Navaratnam, Prakash ^b   Nolte, Hendrik ^c   Gates Jr , Davis F ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b DataMed Solutions LLC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

adolescent; asthma; asthma control; clinical trials; outcome assessment; quality of life; questionnaire

Indexed keywords

FORMOTEROL FUMARATE; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; MOMETASONE FUROATE; PLACEBO; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE; FORMOTEROL; PREGNANE DERIVATIVE;

ADULT; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; ASTHMA QUALITY OF LIFE QUESTIONNAIRE; CHILDHOOD DISEASE; CLINICAL ASSESSMENT; DISEASE CONTROL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; FEMALE; HEALTH CARE QUALITY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PSYCHOMETRY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOCIAL STATUS; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; CHILD; COMPARATIVE STUDY; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PEAK EXPIRATORY FLOW; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CHILD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; MALE; PEAK EXPIRATORY FLOW RATE; PREGNADIENEDIOLS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAL CAPACITY;

EID: 79952150286     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2010.529220     Document Type: Article

References (23)

1. Akinbami LJ, Moorman JE, Garbe PL, Sondik EJ. Status of childhood asthma in the United States, 1980-2007. Pediatrics 2009; 123:S131-S145.
2. Wang LY, Zhong Y, Wheeler L. Direct and indirect costs of asthma in school-age children. Prev Chronic Dis 2005; 2(1) [serial online]. January [October 23, 2009]. Available at: http://www.cdc.gov/pcd/issues/2005/jan/04- 0053.pdf. Accessed September 1, 2010.
3. Williams SA, Wagner S, Kannan H, Bolge SC. The association between asthma control and health care utilization, work productivity loss and health-related quality of life. J Occup Environ Med 2009; 51(7):780-785.
4. Chen H, Gould MK, Miller DP, Kamath TV, Lee JH, et al. Asthma control, severity, and quality of life: Quantifying the effect of uncontrolled disease. J Allergy Clin Immunol 2007; 120(2):396-402. (Pubitemid 47103330)
5. Juniper EF, O'Byrne PM, Roberts JN. Measuring asthma control in group studies: Do we need airway calibre and rescue b2-agonist use?. Respir Med 2001; 95:319-323. (Pubitemid 32624474)
6. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention(updated 2008). Available at: http://www.ginasthma.org/ Guidelineitem.asp??11=2&12=1&intId=60. Accessed March 11, 2009.
7. National Heart, Lung, and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Asthma Education and Prevention Program, National Heart, Lung and Blood Institute, National Institutes of Health. Bethesda, MD; July 2007.
8. Halbert RJ, Tinkelman DG, Globe DR, Lin SL. Measuring asthma control is the first step to patient management: A literature review. J Asthma 2009; 46:659-664.
9. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14:902-907. (Pubitemid 29519356)
10. Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005a; 99:553-558. (Pubitemid 40468501)
11. Wallenstein GV, Carranza-Rosenzweig J, Kosinski M, Blaisdell-Gross B, Gajria K, Jhingran P. A psychometric comparison of three patient-based measures of asthma control. Curr Med Res Opin 2007; 23(2):369-377. (Pubitemid 46333385)
12. de Miguel Díez J, Barcina C, Munoz M, Leal M. Control of persistent asthma in Spain: Associated factors. J Asthma 2008; 45(9):740-746.
13. Lavoie KL, Bacon SL, Cartier A, Ditto B, Labrecque M. What is worse for asthma control and quality of life: Depressive disorders, anxiety disorders, or both? Chest 2006; 130(4):1039-1047.
14. Gergen PJ, Arbes SJ Jr., Calatroni A, Mitchell HE, Zeldin DC. Total IgE levels and asthma prevalence in the US population: Results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2009; 124(3):447-453.
15. Crapo RO. Reference values for lung function tests. Respir Care 1989; 34:626-637. (Pubitemid 19170478)
16. Polgar G, Promadhat V. Pulmonary Function Testing in Children: Techniques and Standards. Philadelphia: WB Saunders Co, 1971.
17. Juniper EF, Svensson K,Mörk AC, Ståhl E. Modification of the asthma quality of life questionnaire (standardised) in patients 12 years and older. Health Qual Life Outcomes 2005; 3:58.
18. Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, Zhang J. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 1997; 10:646-651. (Pubitemid 27112583)
19. Hays R, Revicki DA. Reliability and validity (including responsiveness). In: Fayers P, Hays R, eds. Assessing Quality of Life in Clinical Trials. 2nd ed. New York: Oxford University Press, 2005:25-39.
20. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull 1971; 76(5):378-382.
21. Hinkle DE, Jurs SG, Wiersma W. Applied Statistics for the Behavioral Sciences. Boston: Houghton Mifflin, 1988.
22. Nathan RA, Nolte H, Pearlman DS. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 μg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc 2010; 31:269-279.
23. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: A survey for assessing asthma control. J Allergy Clin Immunol 2004; 113(1):59-65. (Pubitemid 38096162)